NCT00981058 2025-06-18
SQUIRE
Eli Lilly and Company
Phase 3 Completed
Clinical Trials
13 trialsNCT02789345 2024-02-05
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00982111 2022-01-11
INSPIRE
Eli Lilly and Company
Phase 3 Completed
NCT03360734 2021-07-12
GATTO
Glycotope GmbH
Phase 1 Completed
NCT02392507 2020-11-19
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Eli Lilly and Company
Phase 2 Completed
NCT01763788 2019-10-25
A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1/2 Completed
NCT01606748 2019-09-30
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Eli Lilly and Company
Phase 2 Completed
NCT01769391 2019-09-20
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01088464 2017-02-03
Study of IMC-11F8 in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01624467 2016-07-25
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01788566 2016-06-27
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00835185 2016-01-29
Study of IMC-11F8 in Participants With Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00801177 2010-10-13
Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy
Eli Lilly and Company
Phase 1 Completed